Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 4;47(2):824–842. doi: 10.1093/nar/gky1199

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — ITCH nuclear translocation is mediated through an EGF/PI3K/AKT-dependent pathway. (A and B) IB using the indicated antibodies and (C and D) IF imaging using anti-ITCH antibody (red) and DAPI counterstain (blue) of MDA-MB-231 cells before and after 12–18 h 1% serum starvation with or without prior treatment with MK-2206 (0.1 μM), GDC-0941 (0.05 μM), or Erlotinib (1 μM) following the addition of EGF (10 ng/ml). (E and F) IB of cytoplasmic (C) and nuclear (N) cellular compartments. N = 3. The P values indicate significant differences between the experimental groups treated with different inhibitors (MK-2206, GDC-0946, or Erlotinib) and the control groups treated with DMSO under normal or serum-starvation conditions before and after the addition of EGF.